Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | IDH2 | P48735 | 5/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | NEK4 | P51957 | 1/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.41 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621688 | 0.85 | AR (0.56) | ARRORCRIOK2ALDH1A1GAA | |
| SCHEMBL1621037 | 0.82 | CNR1 (0.48) | GAACNR1CNR2 | |
| SCHEMBL1622259 | 0.82 | AR (0.57) | ARRORCRIOK2ALDH1A1GAA | |
| SCHEMBL16253003 | 0.78 | AR (0.58) | ARRORCRIOK2ALDH1A1GAA | |
| SCHEMBL1620990 | 0.78 | CNR2 (0.52) | ARRORCRIOK2ALDH1A1GAA | |
| SCHEMBL1464403 | 0.77 | AR (0.58) | ARRORCRIOK2ALDH1A1GAA | |
| SCHEMBL1464328 | 0.76 | CNR2 (0.65) | ARRORCCNR1CNR2 | |
| SCHEMBL1464145 | 0.76 | AR (0.57) | ARRORCALDH1A1IDH2SORT1 | |
| SCHEMBL1620920 | 0.76 | AR (0.52) | ARRORCRIOK2ALDH1A1GAA | |
| SCHEMBL1621429 | 0.75 | RORC (0.48) | RORCCNR2CLK2MAP4K2HIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | claimed |
| US-7928123-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-19 | — | — | US | claimed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | claimed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-7928123-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-19 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | AR 559/4885RORC 509/4885RIOK2 4762/4885 |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | AR 554/4885RORC 273/4885RIOK2 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.